Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

1.

Adverse events during the Scleroderma Lung Study.

Furst DE, Tseng CH, Clements PJ, Strange C, Tashkin DP, Roth MD, Khanna D, Li N, Elashoff R, Schraufnagel DE; Scleroderma Lung Study.

Am J Med. 2011 May;124(5):459-67. doi: 10.1016/j.amjmed.2010.12.009.

PMID:
21531236
[PubMed - indexed for MEDLINE]
2.

Cyclophosphamide versus placebo in scleroderma lung disease.

Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group.

N Engl J Med. 2006 Jun 22;354(25):2655-66.

PMID:
16790698
[PubMed - indexed for MEDLINE]
Free Article
3.

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM.

Arthritis Rheum. 2006 Dec;54(12):3962-70.

PMID:
17133610
[PubMed - indexed for MEDLINE]
Free Article
4.

Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.

Beretta L, Caronni M, Raimondi M, Ponti A, Viscuso T, Origgi L, Scorza R.

Clin Rheumatol. 2007 Feb;26(2):168-72. Epub 2006 Apr 14.

PMID:
16614793
[PubMed - indexed for MEDLINE]
5.

Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide.

Akesson A, Scheja A, Lundin A, Wollheim FA.

Arthritis Rheum. 1994 May;37(5):729-35.

PMID:
8185701
[PubMed - indexed for MEDLINE]
6.

Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma.

Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PC.

Clin Rheumatol. 1999;18(6):455-61.

PMID:
10638770
[PubMed - indexed for MEDLINE]
7.

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Khanna D, Li N, Li G; Scleroderma Lung Study Research Group.

Am J Respir Crit Care Med. 2007 Nov 15;176(10):1026-34. Epub 2007 Aug 23.

PMID:
17717203
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.

Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG, Chung J, FitzGerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, Mayes MD, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J, Tashkin DP; Scleroderma Lung Study Group.

Arthritis Rheum. 2005 Feb;52(2):592-600.

PMID:
15692967
[PubMed - indexed for MEDLINE]
Free Article
9.

Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.

Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R, Smith EA, Furst DE, Tashkin DP; Scleroderma Lung Study Research Group.

Am J Respir Crit Care Med. 2008 Jan 1;177(1):91-8. Epub 2007 Sep 27.

PMID:
17901414
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial?

Wells AU, Latsi P, McCune WJ.

Am J Respir Crit Care Med. 2007 Nov 15;176(10):952-3. No abstract available.

PMID:
17984310
[PubMed - indexed for MEDLINE]
11.

Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study.

Theodore AC, Tseng CH, Li N, Elashoff RM, Tashkin DP.

Chest. 2012 Sep;142(3):614-21.

PMID:
22156609
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Evaluation and management of scleroderma lung disease using bronchoalveolar lavage.

Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI.

Am J Med. 1990 May;88(5):470-6.

PMID:
2337105
[PubMed - indexed for MEDLINE]
13.

Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study.

Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger TA Jr.

Arthritis Rheum. 1994 Sep;37(9):1290-6.

PMID:
7945491
[PubMed - indexed for MEDLINE]
14.

Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.

Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML, Fulminis A, De Luca A, Farina G, Candela M, Generini S, De Francisci A, Tirri E, Proietti M, Bombardieri S, Gabrielli A, Tonietti G, Cerinic MM.

J Rheumatol. 2002 Apr;29(4):731-6.

PMID:
11950014
[PubMed - indexed for MEDLINE]
15.

Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis.

White B, Moore WC, Wigley FM, Xiao HQ, Wise RA.

Ann Intern Med. 2000 Jun 20;132(12):947-54.

PMID:
10858177
[PubMed - indexed for MEDLINE]
16.

Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.

Kowal-Bielecka O, Kowal K, Rojewska J, Bodzenta-Lukaszyk A, Siergiejko Z, Sierakowska M, Sierakowski S.

Ann Rheum Dis. 2005 Sep;64(9):1343-6.

PMID:
16100339
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease.

Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C.

J Rheumatol. 1993 May;20(5):838-44.

PMID:
8336309
[PubMed - indexed for MEDLINE]
18.

A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.

VĂ¡rai G, Earle L, Jimenez SA, Steiner RM, Varga J.

J Rheumatol. 1998 Jul;25(7):1325-9.

PMID:
9676764
[PubMed - indexed for MEDLINE]
19.

High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.

Wanchu A, Suryanaryana BS, Sharma S, Sharma A, Bambery P.

Int J Rheum Dis. 2009 Sep;12(3):239-42. doi: 10.1111/j.1756-185X.2009.01417.x.

PMID:
20374353
[PubMed - indexed for MEDLINE]
20.

T-889C IL-1alpha promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis.

Beretta L, Cappiello F, Barili M, Bertolotti F, Scorza R.

Clin Rheumatol. 2007 Jan;26(1):88-91. Epub 2006 Apr 25.

PMID:
16636934
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk